

Microbiome Drugs Industry Research Report 2023

<https://marketpublishers.com/r/MA1C4E04C971EN.html>

Date: August 2023

Pages: 103

Price: US\$ 2,950.00 (Single User License)

ID: MA1C4E04C971EN

Abstracts

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Highlights

The global Microbiome Drugs market is projected to reach US\$ million by 2029 from an estimated US\$ million in 2023, at a CAGR of % during 2024 and 2029.

North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.

The Microbiome Drugs market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Microbiome Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the

Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Microbiome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Osel

Product Type Insights

Global markets are presented by Microbiome Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Microbiome Drugs are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

Microbiome Drugs segment by Type

Oral Dosage Form

Enteric Capsules

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Microbiome Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Microbiome Drugs market.

Microbiome Drugs Segment by Symptom

Gastrointestinal Disorders

Autoimmune Disorders

Diabetes

Cancer

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Microbiome Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market

performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Microbiome Drugs industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find

the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Microbiome Drugs companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Microbiome Drugs by Type
 - 2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
 - 2.2.2 Oral Dosage Form
 - 2.2.3 Enteric Capsules
- 2.3 Microbiome Drugs by Symptom
 - 2.3.1 Market Value Comparison by Symptom (2018 VS 2022 VS 2029)
 - 2.3.2 Gastrointestinal Disorders
 - 2.3.3 Autoimmune Disorders
 - 2.3.4 Diabetes
 - 2.3.5 Cancer
 - 2.3.6 Others
- 2.4 Assumptions and Limitations

3 MICROBIOME DRUGS BREAKDOWN DATA BY TYPE

- 3.1 Global Microbiome Drugs Historic Market Size by Type (2018-2023)
- 3.2 Global Microbiome Drugs Forecasted Market Size by Type (2023-2028)

4 MICROBIOME DRUGS BREAKDOWN DATA BY SYMPTOM

- 4.1 Global Microbiome Drugs Historic Market Size by Symptom (2018-2023)
- 4.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2018-2023)

5 GLOBAL GROWTH TRENDS

- 5.1 Global Microbiome Drugs Market Perspective (2018-2029)
- 5.2 Global Microbiome Drugs Growth Trends by Region
 - 5.2.1 Global Microbiome Drugs Market Size by Region: 2018 VS 2022 VS 2029
 - 5.2.2 Microbiome Drugs Historic Market Size by Region (2018-2023)
 - 5.2.3 Microbiome Drugs Forecasted Market Size by Region (2024-2029)
- 5.3 Microbiome Drugs Market Dynamics
 - 5.3.1 Microbiome Drugs Industry Trends
 - 5.3.2 Microbiome Drugs Market Drivers
 - 5.3.3 Microbiome Drugs Market Challenges
 - 5.3.4 Microbiome Drugs Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

- 6.1 Global Top Microbiome Drugs Players by Revenue
 - 6.1.1 Global Top Microbiome Drugs Players by Revenue (2018-2023)
 - 6.1.2 Global Microbiome Drugs Revenue Market Share by Players (2018-2023)
- 6.2 Global Microbiome Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
- 6.3 Global Key Players of Microbiome Drugs Head office and Area Served
- 6.4 Global Microbiome Drugs Players, Product Type & Application
- 6.5 Global Microbiome Drugs Players, Date of Enter into This Industry
- 6.6 Global Microbiome Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

- 7.1 North America Microbiome Drugs Market Size (2018-2029)
- 7.2 North America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 7.3 North America Microbiome Drugs Market Size by Country (2018-2023)
- 7.4 North America Microbiome Drugs Market Size by Country (2024-2029)
- 7.5 United States
- 7.6 Canada

8 EUROPE

- 8.1 Europe Microbiome Drugs Market Size (2018-2029)
- 8.2 Europe Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 8.3 Europe Microbiome Drugs Market Size by Country (2018-2023)

8.4 Europe Microbiome Drugs Market Size by Country (2024-2029)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

9 ASIA-PACIFIC

9.1 Asia-Pacific Microbiome Drugs Market Size (2018-2029)

9.2 Asia-Pacific Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Asia-Pacific Microbiome Drugs Market Size by Country (2018-2023)

9.4 Asia-Pacific Microbiome Drugs Market Size by Country (2024-2029)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

10 LATIN AMERICA

10.1 Latin America Microbiome Drugs Market Size (2018-2029)

10.2 Latin America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Latin America Microbiome Drugs Market Size by Country (2018-2023)

10.4 Latin America Microbiome Drugs Market Size by Country (2024-2029)

9.4 Mexico

9.5 Brazil

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Microbiome Drugs Market Size (2018-2029)

11.2 Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

11.3 Middle East & Africa Microbiome Drugs Market Size by Country (2018-2023)

11.4 Middle East & Africa Microbiome Drugs Market Size by Country (2024-2029)

- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 UAE

12 PLAYERS PROFILED

11.1 Seres Therapeutics

- 11.1.1 Seres Therapeutics Company Detail
- 11.1.2 Seres Therapeutics Business Overview
- 11.1.3 Seres Therapeutics Microbiome Drugs Introduction
- 11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022)
- 11.1.5 Seres Therapeutics Recent Development

11.2 Assembly Biosciences

- 11.2.1 Assembly Biosciences Company Detail
- 11.2.2 Assembly Biosciences Business Overview
- 11.2.3 Assembly Biosciences Microbiome Drugs Introduction
- 11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022)
- 11.2.5 Assembly Biosciences Recent Development

11.3 Synthetic Biologics

- 11.3.1 Synthetic Biologics Company Detail
- 11.3.2 Synthetic Biologics Business Overview
- 11.3.3 Synthetic Biologics Microbiome Drugs Introduction
- 11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022)
- 11.3.5 Synthetic Biologics Recent Development

11.4 Interxon

- 11.4.1 Interxon Company Detail
- 11.4.2 Interxon Business Overview
- 11.4.3 Interxon Microbiome Drugs Introduction
- 11.4.4 Interxon Revenue in Microbiome Drugs Business (2017-2022)
- 11.4.5 Interxon Recent Development

11.5 PureTech

- 11.5.1 PureTech Company Detail
- 11.5.2 PureTech Business Overview
- 11.5.3 PureTech Microbiome Drugs Introduction
- 11.5.4 PureTech Revenue in Microbiome Drugs Business (2017-2022)
- 11.5.5 PureTech Recent Development

11.6 Synlogic

- 11.6.1 Synlogic Company Detail
- 11.6.2 Synlogic Business Overview

- 11.6.3 Synlogic Microbiome Drugs Introduction
- 11.6.4 Synlogic Revenue in Microbiome Drugs Business (2017-2022)
- 11.6.5 Synlogic Recent Development
- 11.7 Enterome BioScience
 - 11.7.1 Enterome BioScience Company Detail
 - 11.7.2 Enterome BioScience Business Overview
 - 11.7.3 Enterome BioScience Microbiome Drugs Introduction
 - 11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022)
 - 11.7.5 Enterome BioScience Recent Development
- 11.8 4D Pharma
 - 11.8.1 4D Pharma Company Detail
 - 11.8.2 4D Pharma Business Overview
 - 11.8.3 4D Pharma Microbiome Drugs Introduction
 - 11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2017-2022)
 - 11.8.5 4D Pharma Recent Development
- 11.9 Second Genome
 - 11.9.1 Second Genome Company Detail
 - 11.9.2 Second Genome Business Overview
 - 11.9.3 Second Genome Microbiome Drugs Introduction
 - 11.9.4 Second Genome Revenue in Microbiome Drugs Business (2017-2022)
 - 11.9.5 Second Genome Recent Development
- 11.10 AOBiome
 - 11.10.1 AOBiome Company Detail
 - 11.10.2 AOBiome Business Overview
 - 11.10.3 AOBiome Microbiome Drugs Introduction
 - 11.10.4 AOBiome Revenue in Microbiome Drugs Business (2017-2022)
 - 11.10.5 AOBiome Recent Development
- 11.11 Rebiotix
 - 11.11.1 Rebiotix Company Detail
 - 11.11.2 Rebiotix Business Overview
 - 11.11.3 Rebiotix Microbiome Drugs Introduction
 - 11.11.4 Rebiotix Revenue in Microbiome Drugs Business (2017-2022)
 - 11.11.5 Rebiotix Recent Development
- 11.12 Metabiomics
 - 11.12.1 Metabiomics Company Detail
 - 11.12.2 Metabiomics Business Overview
 - 11.12.3 Metabiomics Microbiome Drugs Introduction
 - 11.12.4 Metabiomics Revenue in Microbiome Drugs Business (2017-2022)
 - 11.12.5 Metabiomics Recent Development

11.13 Ritter Pharmaceuticals

11.13.1 Ritter Pharmaceuticals Company Detail

11.13.2 Ritter Pharmaceuticals Business Overview

11.13.3 Ritter Pharmaceuticals Microbiome Drugs Introduction

11.13.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022)

11.13.5 Ritter Pharmaceuticals Recent Development

11.14 Symberix

11.14.1 Symberix Company Detail

11.14.2 Symberix Business Overview

11.14.3 Symberix Microbiome Drugs Introduction

11.14.4 Symberix Revenue in Microbiome Drugs Business (2017-2022)

11.14.5 Symberix Recent Development

11.15 OpenBiome

11.15.1 OpenBiome Company Detail

11.15.2 OpenBiome Business Overview

11.15.3 OpenBiome Microbiome Drugs Introduction

11.15.4 OpenBiome Revenue in Microbiome Drugs Business (2017-2022)

11.15.5 OpenBiome Recent Development

11.16 Azitra

11.16.1 Azitra Company Detail

11.16.2 Azitra Business Overview

11.16.3 Azitra Microbiome Drugs Introduction

11.16.4 Azitra Revenue in Microbiome Drugs Business (2017-2022)

11.16.5 Azitra Recent Development

11.17 Osel

11.17.1 Osel Company Detail

11.17.2 Osel Business Overview

11.17.3 Osel Microbiome Drugs Introduction

11.17.4 Osel Revenue in Microbiome Drugs Business (2017-2022)

11.17.5 Osel Recent Development

13 REPORT CONCLUSION

14 DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Symptom (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Microbiome Drugs Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global Microbiome Drugs Revenue Market Share by Type (2018-2023)

Table 7. Global Microbiome Drugs Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global Microbiome Drugs Revenue Market Share by Type (2024-2029)

Table 9. Global Microbiome Drugs Market Size by Symptom (2018-2023) & (US\$ Million)

Table 10. Global Microbiome Drugs Revenue Market Share by Symptom (2018-2023)

Table 11. Global Microbiome Drugs Forecasted Market Size by Symptom (2024-2029) & (US\$ Million)

Table 12. Global Microbiome Drugs Revenue Market Share by Symptom (2024-2029)

Table 13. Global Microbiome Drugs Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global Microbiome Drugs Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global Microbiome Drugs Market Share by Region (2018-2023)

Table 16. Global Microbiome Drugs Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global Microbiome Drugs Market Share by Region (2024-2029)

Table 18. Microbiome Drugs Market Trends

Table 19. Microbiome Drugs Market Drivers

Table 20. Microbiome Drugs Market Challenges

Table 21. Microbiome Drugs Market Restraints

Table 22. Global Top Microbiome Drugs Manufacturers by Revenue (US\$ Million) & (2018-2023)

Table 23. Global Microbiome Drugs Revenue Market Share by Manufacturers (2018-2023)

Table 24. Global Microbiome Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023

Table 25. Global Key Players of Microbiome Drugs, Headquarters and Area Served

Table 26. Global Microbiome Drugs Manufacturers, Product Type & Application

- Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Microbiome Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
- Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
- Table 30. North America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 31. North America Microbiome Drugs Market Size by Country (2018-2023) & (US\$ Million)
- Table 32. North America Microbiome Drugs Market Size by Country (2024-2029) & (US\$ Million)
- Table 33. Europe Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 34. Europe Microbiome Drugs Market Size by Country (2018-2023) & (US\$ Million)
- Table 35. Europe Microbiome Drugs Market Size by Country (2024-2029) & (US\$ Million)
- Table 36. Asia-Pacific Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 37. Asia-Pacific Microbiome Drugs Market Size by Country (2018-2023) & (US\$ Million)
- Table 38. Asia-Pacific Microbiome Drugs Market Size by Country (2024-2029) & (US\$ Million)
- Table 39. Latin America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 40. Latin America Microbiome Drugs Market Size by Country (2018-2023) & (US\$ Million)
- Table 41. Latin America Microbiome Drugs Market Size by Country (2024-2029) & (US\$ Million)
- Table 42. Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 43. Middle East & Africa Microbiome Drugs Market Size by Country (2018-2023) & (US\$ Million)
- Table 44. Middle East & Africa Microbiome Drugs Market Size by Country (2024-2029) & (US\$ Million)
- Table 45. Seres Therapeutics Company Detail
- Table 46. Seres Therapeutics Business Overview
- Table 47. Seres Therapeutics Microbiome Drugs Product
- Table 48. Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)

- Table 49. Seres Therapeutics Recent Development
- Table 50. Assembly Biosciences Company Detail
- Table 51. Assembly Biosciences Business Overview
- Table 52. Assembly Biosciences Microbiome Drugs Product
- Table 53. Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 54. Assembly Biosciences Recent Development
- Table 55. Synthetic Biologics Company Detail
- Table 56. Synthetic Biologics Business Overview
- Table 57. Synthetic Biologics Microbiome Drugs Product
- Table 58. Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 59. Synthetic Biologics Recent Development
- Table 60. Interxon Company Detail
- Table 61. Interxon Business Overview
- Table 62. Interxon Microbiome Drugs Product
- Table 63. Interxon Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 64. Interxon Recent Development
- Table 65. PureTech Company Detail
- Table 66. PureTech Business Overview
- Table 67. PureTech Microbiome Drugs Product
- Table 68. PureTech Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 69. PureTech Recent Development
- Table 70. Synlogic Company Detail
- Table 71. Synlogic Business Overview
- Table 72. Synlogic Microbiome Drugs Product
- Table 73. Synlogic Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 74. Synlogic Recent Development
- Table 75. Enterome BioScience Company Detail
- Table 76. Enterome BioScience Business Overview
- Table 77. Enterome BioScience Microbiome Drugs Product
- Table 78. Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 79. Enterome BioScience Recent Development
- Table 80. 4D Pharma Company Detail
- Table 81. 4D Pharma Business Overview
- Table 82. 4D Pharma Microbiome Drugs Product
- Table 83. 4D Pharma Revenue in Microbiome Drugs Business (2017-2022) & (US\$

Million)

Table 84. 4D Pharma Recent Development

Table 85. Second Genome Company Detail

Table 86. Second Genome Business Overview

Table 87. Second Genome Microbiome Drugs Product

Table 88. Second Genome Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)

Table 89. Second Genome Recent Development

Table 90. AOBiome Company Detail

Table 91. AOBiome Business Overview

Table 92. AOBiome Microbiome Drugs Product

Table 93. AOBiome Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)

Table 94. AOBiome Recent Development

Table 95. Rebiotix Company Detail

Table 96. Rebiotix Business Overview

Table 97. Rebiotix Microbiome Drugs Product

Table 98. Rebiotix Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)

Table 99. Rebiotix Recent Development

Table 100. Metabionics Company Detail

Table 101. Metabionics Business Overview

Table 102. Metabionics Microbiome Drugs Product

Table 103. Metabionics Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)

Table 104. Metabionics Recent Development

Table 105. Ritter Pharmaceuticals Company Detail

Table 106. Ritter Pharmaceuticals Business Overview

Table 107. Ritter Pharmaceuticals Microbiome Drugs Product

Table 108. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)

Table 109. Ritter Pharmaceuticals Recent Development

Table 110. Syberix Company Detail

Table 111. Syberix Business Overview

Table 112. Syberix Microbiome Drugs Product

Table 113. Syberix Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)

Table 114. Syberix Recent Development

Table 115. OpenBiome Company Detail

Table 116. OpenBiome Business Overview

- Table 117. OpenBiome Microbiome DrugsProduct
- Table 118. OpenBiome Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 119. OpenBiome Recent Development
- Table 120. Azitra Company Detail
- Table 121. Azitra Business Overview
- Table 122. Azitra Microbiome DrugsProduct
- Table 123. Azitra Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 124. Azitra Recent Development
- Table 125. Osel Company Detail
- Table 126. Osel Business Overview
- Table 127. Osel Microbiome DrugsProduct
- Table 128. Osel Revenue in Microbiome Drugs Business (2017-2022) & (US\$ Million)
- Table 129. Osel Recent Development
- Table 130. Seres Therapeutics Company Information
- Table 131. Seres Therapeutics Business Overview
- Table 132. Seres Therapeutics Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 133. Seres Therapeutics Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 134. Seres Therapeutics Recent Development
- Table 135. Assembly Biosciences Company Information
- Table 136. Assembly Biosciences Business Overview
- Table 137. Assembly Biosciences Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 138. Assembly Biosciences Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 139. Assembly Biosciences Recent Development
- Table 140. Synthetic Biologics Company Information
- Table 141. Synthetic Biologics Business Overview
- Table 142. Synthetic Biologics Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 143. Synthetic Biologics Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 144. Synthetic Biologics Recent Development
- Table 145. Interxon Company Information
- Table 146. Interxon Business Overview
- Table 147. Interxon Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

- Table 148. Interxon Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 149. Interxon Recent Development
- Table 150. PureTech Company Information
- Table 151. PureTech Business Overview
- Table 152. PureTech Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 153. PureTech Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 154. PureTech Recent Development
- Table 155. Synlogic Company Information
- Table 156. Synlogic Business Overview
- Table 157. Synlogic Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 158. Synlogic Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 159. Synlogic Recent Development
- Table 160. Enterome BioScience Company Information
- Table 161. Enterome BioScience Business Overview
- Table 162. Enterome BioScience Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 163. Enterome BioScience Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 164. Enterome BioScience Recent Development
- Table 165. 4D Pharma Company Information
- Table 166. 4D Pharma Business Overview
- Table 167. 4D Pharma Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 168. 4D Pharma Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 169. 4D Pharma Recent Development
- Table 170. Second Genome Company Information
- Table 171. Second Genome Business Overview
- Table 172. Second Genome Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)
- Table 173. Second Genome Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 174. Second Genome Recent Development
- Table 175. AOBiome Company Information

Table 176. AOBiome Business Overview

Table 177. AOBiome Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 178. AOBiome Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 179. AOBiome Recent Development

Table 180. Rebiotix Company Information

Table 181. Rebiotix Business Overview

Table 182. Rebiotix Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 183. Rebiotix Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 184. Rebiotix Recent Development

Table 185. Metabionics Company Information

Table 186. Metabionics Business Overview

Table 187. Metabionics Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 188. Metabionics Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 189. Metabionics Recent Development

Table 190. Ritter Pharmaceuticals Company Information

Table 191. Ritter Pharmaceuticals Business Overview

Table 192. Ritter Pharmaceuticals Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 193. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 194. Ritter Pharmaceuticals Recent Development

Table 195. Syberix Company Information

Table 196. Syberix Business Overview

Table 197. Syberix Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 198. Syberix Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 199. Syberix Recent Development

Table 200. OpenBiome Company Information

Table 201. OpenBiome Business Overview

Table 202. OpenBiome Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 203. OpenBiome Revenue in Microbiome Drugs Business (2018-2023) & (US\$

Million) Portfolio

Table 204. OpenBiome Recent Development

Table 205. Azitra Company Information

Table 206. Azitra Business Overview

Table 207. Azitra Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 208. Azitra Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 209. Azitra Recent Development

Table 210. Osel Company Information

Table 211. Osel Business Overview

Table 212. Osel Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million)

Table 213. Osel Revenue in Microbiome Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 214. Osel Recent Development

Table 215. Authors List of This Report

List Of Figures

LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Microbiome Drugs Product Picture

Figure 5. Global Microbiome Drugs Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 6. Global Microbiome Drugs Market Share by Type: 2022 VS 2029

Figure 7. Oral Dosage Form Product Picture

Figure 8. Enteric Capsules Product Picture

Figure 9. Global Microbiome Drugs Market Size by Symptom (2023-2029) & (US\$ Million)

Figure 10. Global Microbiome Drugs Market Share by Symptom: 2022 VS 2029

Figure 11. Gastrointestinal Disorders Product Picture

Figure 12. Autoimmune Disorders Product Picture

Figure 13. Diabetes Product Picture

Figure 14. Cancer Product Picture

Figure 15. Others Product Picture

Figure 16. Global Microbiome Drugs Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 17. Global Microbiome Drugs Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 18. Global Microbiome Drugs Market Share by Region: 2022 VS 2029

Figure 19. Global Microbiome Drugs Market Share by Players in 2022

Figure 20. Global Microbiome Drugs Players, Date of Enter into This Industry

Figure 21. Global Top 5 and 10 Microbiome Drugs Players Market Share by Revenue in 2022

Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 23. North America Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. North America Microbiome Drugs Market Share by Country (2018-2029)

Figure 25. United States Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Canada Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Europe Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

- Figure 28. Europe Microbiome Drugs Market Share by Country (2018-2029)
- Figure 29. Germany Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 30. France Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 31. U.K. Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 32. Italy Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 33. Russia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 34. Nordic Countries Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 35. Asia-Pacific Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 36. Asia-Pacific Microbiome Drugs Market Share by Country (2018-2029)
- Figure 37. China Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 38. Japan Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 39. South Korea Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 40. Southeast Asia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 41. India Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 42. Australia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 43. Latin America Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 44. Latin America Microbiome Drugs Market Share by Country (2018-2029)
- Figure 45. Mexico Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 46. Brazil Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 47. Middle East & Africa Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 48. Middle East & Africa Microbiome Drugs Market Share by Country (2018-2029)
- Figure 49. Turkey Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Million)

Figure 50. Saudi Arabia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 51. UAE Microbiome Drugs Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 52. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 53. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 54. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 55. Interxon Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 56. PureTech Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 57. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 58. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 59. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 60. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 61. AOBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 62. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 63. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 64. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 65. Symberix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 66. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 67. Azitra Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

Figure 68. Osel Revenue Growth Rate in Microbiome Drugs Business (2018-2023)

I would like to order

Product name: Microbiome Drugs Industry Research Report 2023

Product link: <https://marketpublishers.com/r/MA1C4E04C971EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA1C4E04C971EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970